PLoS ONE · 2013 · 78 citations · 25 references
The limited symptom relief and side effects of current Alzheimer's disease (AD) medications warrant urgent discovery and study of new anti-AD agents. The "cholinergic hypothesis" of AD prompts us to search for plant-derived acetylcholineesterase (AChE) inhibitors such as galanthamine that has been licensed in Europe for AD treatment. We used the unique amyloid β-expressing transgenic C. elegans CL4176, which exhibits paralysis when human Aβ1-42 is induced, to study two natural benzylphenethylamine alkaloids isolated from Lycoris radiata (L' Her.) Herb, galanthamine and haemanthidine, and their synthetic derivatives 1,2-Di-O-acetyllycorine and 1-O-acetyllycorine for their anti-paralysis effects. Our data indicate that these Lycoris compounds effectively delay the paralysis of CL4176 worms upon temperature up-shift, and prolong the lives of these transgenic worms. Lycoris compounds were shown to significantly inhibit the gene expression of ace-1 and ace-2. Additionally, the Lycoris compounds may modulate inflammatory and stress-related gene expressions to combat the Aβ-toxicity in C. elegans.
25
Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation
Hong Wang, Man Yu, Mahendar Ochani et al. · Nature · 2002 · 3.1K citations
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Kwasi G. Mawuenyega, Wendy Sigurdson, Vitaliy Ovod et al. · Science · 2010 · 2K citations · Full text
Steven W. Barger, D Hörster, Koichi Furukawa et al. · Proceedings of the National Academy of Sciences · 1995 · 625 citations · Full text